Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is a single-center (Emory University), open-label, single arm, phase I study to assess
safety and toxicity of bortezomib in combination with bevacizumab and escalating doses of
temozolomide for patients with recurrent glioblastoma multiforme. Patients requiring
anti-epileptic medications will have to be at least 10 days off EIAEDs. Only non-EIAEDs are
accepted.
Phase:
Phase 1
Details
Lead Sponsor:
Emory University
Collaborators:
Genentech, Inc. Millennium Pharmaceuticals, Inc. Schering-Plough